General Biotechnology

Evergreen-ing is the headline everybody usesright up until you try to separate marketing from mechanics.
In a world where a single branded medicine can generate billions in revenue, the patent system becomes more than a legal framework. It becomes stra…

The quiet ROI of suing early: Why weak method-of-use patents are often the best place to start
Patent litigation in pharma has a reputation for being expensive, slow, and ugly. But thats only half the story.
The other half is happening quietlyinside th…

The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
If youve been anywhere near generic drug strategy, youve heard it: win the first-to-file race and you get 180 days of exclusivity. It sounds like a built-in moattime to recoup R&a…

Most pharma teams treat settlement like a win button. In court, that mindset is expensive.
Theres a familiar script in drug litigation: if the dispute is hard, settle. If the numbers look uncertain, settle. If the optics get messy, settle.
But drug…

A device patent challenge often doesnt start with the biggest cracksit starts with the weakest wall.
In pharma, its easy to think of a patent portfolio as a fortress: layered, fortified, and designed to keep generic competition at bay. But litigation a…

The Salt Change Trap: When a New Patent Buys You Nothing
Pharmaceutical patents are supposed to protect breakthroughsnot reroute competition through legal shell games. But in recent years, a quiet strategy has become increasingly common: the salt chang…

Bausch + the burden of proof: what no, it wasnt obvious really looks like in a modern patent case
If youve ever wondered whats actually at stake when a pharma patent dispute heads to court, this case is a reminder that the fight isnt just about drugsit…

Exelixis vs. Intas: When Generic Isnt a WordIts a Strategy
Theres a recurring misunderstanding in biotech: that generic competition is a straight linepatents fall, approvals follow, prices drop.
In reality, the biotech IP battleground is often a labyri…

Amneal vs. Alembic: The Quiet Legal Chess Match That Can Move Drug Prices
In pharma, the most consequential battles often dont play out in factories or boardroomsthey play out in courtrooms, in the language of patents, and in the fine print of regulato…

🚨 A pivotal patent case is quietly signaling the next phase of competition in oncologyand the real winners may not be the ones you expect.
On its surface, Exelixis, Inc. v. Handa Pharmaceuticals Inc. looks like another day at the patent courthouse. …